News | September 12, 2025
A.forall expands US generics portfolio
Four FDA-approved products strengthen portfolio and reaffirm commitment to global reach
Four FDA-approved products strengthen portfolio and reaffirm commitment to global reach
Transformation to increase speed and redirect resources to growth opportunities within diabetes and obesity, aiming at reaching millions of untreated patients
Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease
MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity
Funding to support Phase 2b trial with MRM Health’s lead program MH002 in ulcerative colitis and advance two additional programs to IND approval
Agreement further expands Aptar Pharma’s leading position in nasal delivery solutions and addresses significant unmet needs of delivering drugs locally over extended periods
These licenses are given in areas of infectious disease diagnostics, immunodiagnostics, and vaccine development
Under the partnership, the Pfizer INDovation program will empower DPIIT-recognized startups with grants of up to Rs. 60 lakhs each, along with a tailored 18-month incubation program delivered by Social Alpha
Subscribe To Our Newsletter & Stay Updated
